Paroxetine protects against bleomycin-induced pulmonary fibrosis by blocking GRK2/Smad3 pathway

Area of Science:

• Pharmacology
• Pulmonary Medicine
• Cell Biology

Background:

• G protein-coupled receptor kinase-2 (GRK2) plays a role in the pathogenesis of pulmonary fibrosis.
• Paroxetine (PRXT) is a known selective GRK2 inhibitor used for anxiety and depression.
• The efficacy of PRXT in treating pulmonary fibrosis is not yet established.

Purpose of the Study:

• To investigate the effects of PRXT on bleomycin-induced pulmonary fibrosis in mice.
• To examine the impact of PRXT on TGF-β1-induced activation of primary lung fibroblasts.
• To elucidate the molecular mechanisms underlying PRXT's potential anti-fibrotic effects.

Main Methods:

• Bleomycin-induced pulmonary fibrosis model in C57/BL6 mice.
• Primary murine lung fibroblast culture stimulated with TGF-β1.
• Assessment of pulmonary function, survival rates, collagen deposition, inflammation, and oxidative stress.
• Analysis of GRK2 and Smad3 protein and mRNA expression.
• Smad3 overexpression experiments using adenovirus transfection.

Main Results:

• PRXT significantly improved pulmonary function and 21-day survival in bleomycin-induced mice.
• PRXT treatment reduced collagen deposition, inflammation, and oxidative stress in lung tissues.
• PRXT inhibited GRK2 and Smad3 expression in vivo and in vitro.
• PRXT suppressed lung fibroblast activation and collagen synthesis in a dose-dependent manner.
• Smad3 overexpression counteracted the anti-fibrotic and antioxidative effects of PRXT.

Conclusions:

• PRXT demonstrates significant therapeutic potential for pulmonary fibrosis.
• PRXT exerts its anti-fibrotic effects by inhibiting GRK2, which subsequently blocks Smad3 transcription.
• The GRK2-Smad3 pathway represents a promising therapeutic target for pulmonary fibrosis treatment.